Literature DB >> 26234899

Therapeutic effect for liver-metastasized tumor by sequential intravenous injection of anionic polymer and cationic lipoplex of siRNA.

Yoshiyuki Hattori1, Shohei Arai1, Takuto Kikuchi1, Kei-Ichi Ozaki2, Kumi Kawano1, Etsuo Yonemochi1.   

Abstract

Previously, we developed a novel siRNA transfer method to the liver by sequential intravenous injection of anionic polymer and cationic liposome/siRNA complex (cationic lipoplex). In this study, we investigated whether siRNA delivered by this sequential injection could significantly suppress mRNA expression of the targeted gene in liver metastasis and inhibit tumor growth. When cationic lipoplex was intravenously injected into mice bearing liver metastasis of human breast tumor MCF-7 at 1 min after intravenous injection of chondroitin sulfate C (CS) or poly-l-glutamic acid (PGA), siRNA was accumulated in tumor-metastasized liver. In terms of a gene silencing effect, sequential injections of CS or PGA plus cationic lipoplex of luciferase siRNA could reduce luciferase activity in liver MCF-7-Luc metastasis. Regarding the side effects, sequential injections of CS plus cationic lipoplex did not exhibit hepatic damage or induction of inflammatory cytokines in serum after repeated injections, but sequential injections of PGA plus cationic lipoplex did. Finally, sequential injections of CS plus cationic lipoplex of protein kinase N3 siRNA could suppress tumor growth in the mice bearing liver metastasis. From these findings, sequential injection of CS and cationic lipoplex of siRNA might be a novel systemic method of delivering siRNA to liver metastasis.

Entities:  

Keywords:  Chondroitin sulfate; gene silencing; liposome; liver metastasis; poly-l-glutamic acid; siRNA delivery

Mesh:

Substances:

Year:  2015        PMID: 26234899     DOI: 10.3109/1061186X.2015.1070856

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

Review 1.  Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.

Authors:  Deidra M Ward; Aaliyah B Shodeinde; Nicholas A Peppas
Journal:  Adv Healthc Mater       Date:  2021-05-11       Impact factor: 11.092

2.  Evaluation of in vitro and in vivo therapeutic antitumor efficacy of transduction of polo-like kinase 1 and heat shock transcription factor 1 small interfering RNA.

Authors:  Yoshiyuki Hattori; Takuto Kikuchi; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Exp Ther Med       Date:  2017-08-28       Impact factor: 2.447

3.  Therapeutic effects of protein kinase N3 small interfering RNA and doxorubicin combination therapy on liver and lung metastases.

Authors:  Yoshiyuki Hattori; Takuto Kikuchi; Mari Nakamura; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Oncol Lett       Date:  2017-08-25       Impact factor: 2.967

4.  Effects of sterol derivatives in cationic liposomes on biodistribution and gene-knockdown in the lungs of mice systemically injected with siRNA lipoplexes.

Authors:  Yoshiyuki Hattori; Hiromu Saito; Teruaki Oku; Kei-Ichi Ozaki
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

5.  Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice.

Authors:  Yoshiyuki Hattori; Kyoko Tamaki; Sho Sakasai; Kei-Ichi Ozaki; Hiraku Onishi
Journal:  Mol Med Rep       Date:  2020-09-18       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.